AR083422A1 - Composiciones y metodos para tratar la hipertension pulmonar - Google Patents
Composiciones y metodos para tratar la hipertension pulmonarInfo
- Publication number
- AR083422A1 AR083422A1 ARP110103833A ARP110103833A AR083422A1 AR 083422 A1 AR083422 A1 AR 083422A1 AR P110103833 A ARP110103833 A AR P110103833A AR P110103833 A ARP110103833 A AR P110103833A AR 083422 A1 AR083422 A1 AR 083422A1
- Authority
- AR
- Argentina
- Prior art keywords
- pharmaceutically acceptable
- ambrisentan
- tadalafil
- therapeutically effective
- group
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Abstract
Formulaciones que comprenden cantidades terapéuticamente efectivas de ambrisentan o una sal farmacéuticamente aceptable del mismo y tadalafil o una sal farmacéuticamente aceptable del mismo y métodos para tratar y/o prevenir la hipertensión pulmonar por administración de las formulaciones.Reivindicación 1: Una formulación farmacéutica caracterizada porque comprende: una cantidad terapéuticamente efectiva de un antagonista selectivo del receptor de endotelina de tipo A (ERA) que se selecciona entre el grupo que consiste en ambrisentan, sitaxsentan y sales farmacéuticamente aceptables de los mismos, y una cantidad terapéuticamente efectiva de un inhibidor de fosfodiesterasa de tipo 5 (PDE5) que se selecciona entre el grupo que consiste en sildenafil, tadalafil, vardenafil y sales farmacéuticamente aceptables de los mismos, donde la proporción en peso entre el ERA selectivo de tipo A y el inhibidor de PDE5 se encuentra dentro del rango entre aproximadamente 1:1 y aproximadamente 1:10. Reivindicación 14: La formulación farmacéutica de la reivindicación 1, caracterizada porque además comprende un tercer agente activo que comprende por lo menos una droga que se selecciona entre el grupo que consiste en prostanoides, inhibidores de PDE5 diferentes del tadalafil, antagonistas del receptor de endotelina diferentes del ambrisentan, bloqueantes del canal de calcio, diuréticos, anticoagulantes, oxígeno y combinaciones de los mismos.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US39352910P | 2010-10-15 | 2010-10-15 | |
US201161490454P | 2011-05-26 | 2011-05-26 | |
US201161497475P | 2011-06-15 | 2011-06-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR083422A1 true AR083422A1 (es) | 2013-02-21 |
Family
ID=45939010
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP110103833A AR083422A1 (es) | 2010-10-15 | 2011-10-17 | Composiciones y metodos para tratar la hipertension pulmonar |
Country Status (25)
Country | Link |
---|---|
US (3) | US20120269898A1 (es) |
EP (2) | EP3106163A1 (es) |
JP (2) | JP5806320B2 (es) |
KR (2) | KR20150002876A (es) |
CN (1) | CN103458690B (es) |
AR (1) | AR083422A1 (es) |
AU (2) | AU2011315891B2 (es) |
BR (1) | BR112013008983A2 (es) |
CA (1) | CA2814518C (es) |
CY (1) | CY1119007T1 (es) |
DK (1) | DK2637664T3 (es) |
EA (2) | EA026074B1 (es) |
ES (1) | ES2627944T3 (es) |
HR (1) | HRP20170848T1 (es) |
HU (1) | HUE033346T2 (es) |
LT (1) | LT2637664T (es) |
MX (1) | MX346730B (es) |
NZ (2) | NZ610012A (es) |
PL (1) | PL2637664T3 (es) |
PT (1) | PT2637664T (es) |
RS (1) | RS56135B1 (es) |
SI (1) | SI2637664T1 (es) |
TW (1) | TWI542580B (es) |
WO (1) | WO2012051559A2 (es) |
ZA (1) | ZA201302746B (es) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2101777B1 (en) | 2006-12-12 | 2015-05-20 | Gilead Sciences, Inc. | Composition for treating a pulmonary hypertension |
MX346730B (es) | 2010-10-15 | 2017-03-30 | Gilead Sciences Inc | Composiciones y metodos para el tratamiento de la hipertension pulmonar. |
WO2014003678A1 (en) * | 2012-06-28 | 2014-01-03 | Xspray Microparticles Ab | Pharmaceutical compositions comprising ambrisentan and solid dispersion particles containing tadalafil |
WO2014174529A2 (en) * | 2013-04-23 | 2014-10-30 | Hetero Research Foundation | Polymorphs of avanafil |
WO2015069839A1 (en) * | 2013-11-06 | 2015-05-14 | Gilead Sciences, Inc. | Combination therapy for treating pulmonary hypertension |
CN105581990A (zh) * | 2014-08-27 | 2016-05-18 | 人福医药集团股份公司 | 安立生坦片剂及其制备方法 |
CA2982436C (en) | 2015-03-13 | 2023-09-12 | Indiana University Research And Technology Corporation | Targeting cgmp-related phosphodiesterases to reduce cyst formation in cystic kidney disease, and related materials and methods |
RS62011B1 (sr) * | 2016-07-15 | 2021-07-30 | Acceleron Pharma Inc | Kompozicije koje sadrže polipeptide actriia za upotrebu u lečenju plućne hipertenzije |
CA3041679A1 (en) | 2016-10-27 | 2018-05-03 | Lawrence S. ZISMAN | Combination therapy for treating pulmonary hypertension |
WO2019010445A1 (en) * | 2017-07-07 | 2019-01-10 | The Regents Of The University Of Colorado, A Body Corporate | COMPOSITIONS AND METHOD FOR THE TREATMENT OF PULMONARY HYPERTENSION |
JP2021509114A (ja) | 2017-12-26 | 2021-03-18 | エフティーエフ ファーマ プライベート リミテッド | Pde v阻害剤のための液体経口処方物 |
CN109406688A (zh) * | 2018-09-28 | 2019-03-01 | 中国食品药品检定研究院 | 用于检测产品中违禁药品的标准样品 |
MX2022006403A (es) * | 2019-11-29 | 2022-08-25 | Actelion Pharmaceuticals Ltd | Metodos de tratamiento de hipertension de la arteria pulmonar. |
CA3161960A1 (en) | 2019-12-16 | 2021-06-24 | Tenax Therapeutics, Inc. | Levosimendan for treating pulmonary hypertension with heart failure with preserved ejection fraction (ph-hfpef) |
KR102606504B1 (ko) * | 2020-04-10 | 2023-11-29 | 주식회사 대웅테라퓨틱스 | 니클로사마이드를 포함하는 폐고혈압의 예방 및 치료용 조성물 |
CN112826944B (zh) * | 2021-01-29 | 2023-08-15 | 台州职业技术学院 | 一种安立生坦包合物及其制备方法 |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
US4326525A (en) | 1980-10-14 | 1982-04-27 | Alza Corporation | Osmotic device that improves delivery properties of agent in situ |
US5364620A (en) | 1983-12-22 | 1994-11-15 | Elan Corporation, Plc | Controlled absorption diltiazem formulation for once daily administration |
US4902514A (en) | 1988-07-21 | 1990-02-20 | Alza Corporation | Dosage form for administering nilvadipine for treating cardiovascular symptoms |
US5250534A (en) | 1990-06-20 | 1993-10-05 | Pfizer Inc. | Pyrazolopyrimidinone antianginal agents |
DE4313412A1 (de) | 1993-04-23 | 1994-10-27 | Basf Ag | 3-(Het)aryl-Carbonsäurederivate, Verfahren und Zwischenprodukte zu ihrer Herstellung |
GB9401090D0 (en) | 1994-01-21 | 1994-03-16 | Glaxo Lab Sa | Chemical compounds |
DE19533023B4 (de) | 1994-10-14 | 2007-05-16 | Basf Ag | Neue Carbonsäurederivate, ihre Herstellung und Verwendung |
SK287161B6 (sk) | 1997-11-12 | 2010-02-08 | Bayer Healthcare Ag | 2-Fenylsubstituované imidazotriazinóny, spôsob ich výroby, liečivá obsahujúce tieto látky a ich použitie |
US6821975B1 (en) | 1999-08-03 | 2004-11-23 | Lilly Icos Llc | Beta-carboline drug products |
EP1776108A1 (en) | 2004-06-23 | 2007-04-25 | Myogen, Inc. | Enoximone formulations and their use in the treatment of pde-iii mediated diseases |
US20060205733A1 (en) | 2004-08-26 | 2006-09-14 | Encysive Pharmaceuticals | Endothelin a receptor antagonists in combination with phosphodiesterase 5 inhibitors and uses thereof |
CN101072564A (zh) * | 2004-08-26 | 2007-11-14 | 恩希赛弗制药公司 | 内皮缩血管肽a受体(eta)拮抗剂与磷酸二酯酶5(pde5)抑制剂的联合及其用途 |
ATE513831T1 (de) | 2006-04-21 | 2011-07-15 | Pfizer Prod Inc | Pyridinä3,4-büpyrazinone |
EP2101777B1 (en) | 2006-12-12 | 2015-05-20 | Gilead Sciences, Inc. | Composition for treating a pulmonary hypertension |
EP2091539A1 (en) * | 2006-12-12 | 2009-08-26 | Gilead Colorado, Inc. | Ambrisentan combined with a renin inhibitor for hypertensive disorder |
EP2183223A2 (en) | 2007-07-31 | 2010-05-12 | Gilead Colorado, Inc. | Metabolites and derivatives of ambrisentan |
WO2010062640A1 (en) | 2008-10-28 | 2010-06-03 | Gilead Colorado, Inc. | Methods for treating idiopathic pulmonary fibrosis and associated complications |
MX346730B (es) | 2010-10-15 | 2017-03-30 | Gilead Sciences Inc | Composiciones y metodos para el tratamiento de la hipertension pulmonar. |
-
2011
- 2011-10-14 MX MX2013004190A patent/MX346730B/es active IP Right Grant
- 2011-10-14 JP JP2013534043A patent/JP5806320B2/ja not_active Expired - Fee Related
- 2011-10-14 KR KR20147032816A patent/KR20150002876A/ko not_active Application Discontinuation
- 2011-10-14 RS RS20170640A patent/RS56135B1/sr unknown
- 2011-10-14 ES ES11833507.4T patent/ES2627944T3/es active Active
- 2011-10-14 US US13/274,013 patent/US20120269898A1/en not_active Abandoned
- 2011-10-14 LT LTEP11833507.4T patent/LT2637664T/lt unknown
- 2011-10-14 EP EP16180914.0A patent/EP3106163A1/en not_active Withdrawn
- 2011-10-14 PT PT118335074T patent/PT2637664T/pt unknown
- 2011-10-14 TW TW100137481A patent/TWI542580B/zh not_active IP Right Cessation
- 2011-10-14 EP EP11833507.4A patent/EP2637664B1/en not_active Revoked
- 2011-10-14 DK DK11833507.4T patent/DK2637664T3/en active
- 2011-10-14 WO PCT/US2011/056404 patent/WO2012051559A2/en active Application Filing
- 2011-10-14 BR BR112013008983A patent/BR112013008983A2/pt not_active IP Right Cessation
- 2011-10-14 SI SI201131190A patent/SI2637664T1/sl unknown
- 2011-10-14 PL PL11833507T patent/PL2637664T3/pl unknown
- 2011-10-14 NZ NZ610012A patent/NZ610012A/en active IP Right Revival
- 2011-10-14 EA EA201390428A patent/EA026074B1/ru active IP Right Revival
- 2011-10-14 HU HUE11833507A patent/HUE033346T2/en unknown
- 2011-10-14 AU AU2011315891A patent/AU2011315891B2/en active Active
- 2011-10-14 NZ NZ707213A patent/NZ707213A/en active IP Right Revival
- 2011-10-14 CA CA2814518A patent/CA2814518C/en not_active Expired - Fee Related
- 2011-10-14 KR KR1020137012382A patent/KR20130069855A/ko active Search and Examination
- 2011-10-14 EA EA201691759A patent/EA201691759A1/ru unknown
- 2011-10-14 CN CN201180060879.3A patent/CN103458690B/zh not_active Expired - Fee Related
- 2011-10-17 AR ARP110103833A patent/AR083422A1/es unknown
-
2013
- 2013-04-17 ZA ZA2013/02746A patent/ZA201302746B/en unknown
- 2013-11-13 US US14/079,548 patent/US9549926B2/en active Active
-
2015
- 2015-06-10 JP JP2015117196A patent/JP2015178528A/ja not_active Withdrawn
-
2016
- 2016-07-04 AU AU2016204638A patent/AU2016204638B2/en not_active Ceased
- 2016-08-09 US US15/232,570 patent/US20160346280A1/en not_active Abandoned
-
2017
- 2017-06-05 HR HRP20170848TT patent/HRP20170848T1/hr unknown
- 2017-06-22 CY CY20171100660T patent/CY1119007T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR083422A1 (es) | Composiciones y metodos para tratar la hipertension pulmonar | |
AR124134A2 (es) | Formulación de uso tópico para un inhibidor de jak | |
ECSP066990A (es) | Formulaciones con liberación controlada de principio activo que contienen vardenafilo | |
CL2017003445A1 (es) | Formas solidas y formulaciones de compuestos de imidazopirazina. | |
CY1122853T1 (el) | Σταθερα σκευασματα λινακλοτιδης | |
SI2989100T1 (en) | NAFTIRIDINE DERIVATIVES USED AS ANTAGONISTS INTEGRITY OF ALFA-V-BETA-6 | |
PE20190390A1 (es) | Formas cristalinas de un inhibidor de tirosina quinasa de bruton | |
CY1117352T1 (el) | Υποκατεστημενες ιμιδαζοπυριδαζiνες | |
PE20150637A1 (es) | Derivados de pirrolotriazinona como inhibidores de pi3k | |
PE20151501A1 (es) | Inhibidores de prmt5 y sus usos | |
CO6680640A2 (es) | Uso de aglutinantes para fabircar formulaciones estables al almacenamiento | |
PE20150998A1 (es) | Inhibidores de histona demetilasas | |
PE20120371A1 (es) | 3-[4-(7h-pirrolo[2,3-d]pirimidin-4il)-1h-pirazol-1-il]octano o heptano-nitrilo como inhibidores de jak | |
UY37160A (es) | COMPUESTOS DERIVADOS DE PIRROLIDINA CON ACTIVIDAD ANTAGONISTA DE INTEGRINA avß6 | |
DOP2010000064A (es) | 2-anilinopurin 8-onas como inhibidores de ttk/mps1 para el tratamiento de trastornos proliferativos | |
CL2013000677A1 (es) | Composicion farmaceutica en forma de tabletas que comprenden microgranulos gastrointestinales que contienen 100 a 800 mg de rifaximina, hasta 30% p/p de excipientes extragranulares y un recubrimiento formador de pelicula; y uso para tratar una enfermedad infecciosa y/o inflamatoria del intestino, tal como la enfermedad de crohn. | |
IN2014MN01919A (es) | ||
CO6220902A2 (es) | Formulacion en polvo del valganciclovir | |
AR096045A1 (es) | Composición farmacéutica y formulación para prevenir o tratar el síndrome de ojo seco | |
EA201891267A1 (ru) | Фармацевтическая композиция, содержащая действенный ингибитор urat1 | |
PE20160550A1 (es) | Formulaciones de (s)-3-(4-((4-(morfolinometil)bencil)oxi)-1-oxoisoindolin-2-il)piperidin-2,6-diona | |
CO6361855A2 (es) | Derivados de 7-hidroxi-benzoimidazol-4-il-,etanona e inhibidores de cinasa que enlaza pdz que contienen los mismos | |
BR112012029064A2 (pt) | formulação farmacêutica na forma de comprimidos de duas camadas compreendendo inibidores da hmg-coa redutase e irbesartan | |
ECSP099382A (es) | Sulfonamidas heterocíclicos que tienen actividad antagonista edg-i | |
MX2016014771A (es) | Forma de dosificacion oralmente desintegrante para administracion de avanafil, y metodos de fabricacion y uso asociados. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |